Skip to main content
ACR Advocacy Update
Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. 
Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA.
-Pts with nail involvem

Adela Castro AdelaCastro222

1 year 9 months ago
Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA. -Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52. -IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ
3D management of Sscl from @delgaldoFrances
-Time
-Severity
-Type of organ involvement

*Identify phenotypes: fibrotic

Adela Castro AdelaCastro222

1 year 9 months ago
3D management of Sscl from @delgaldoFrances -Time -Severity -Type of organ involvement *Identify phenotypes: fibrotic vs vascular damage. *Raynaud’s red flags: +ANA, puffy fingers, abn capillaroscopy. *Early ttnt of of digital ulcers delays onset of PAH. *High IFN-I =marker of… https://t.co/ByfuV0MJds https://t.co/GdRVwuRf4E
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
DISH in SpA
With the advent of FDA-approved anti-obesity medications such as semaglutide and tirzepatide, a new avenue for managing this challenging patient population has emerged. But how might these drugs impact the trajectory of RA, and are we on the cusp of a paradigm shift?
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now

Richard Conway RichardPAConway

1 year 9 months ago
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse
×